|
Age at initial diagnosis, years
|
|
≥55 vs. <55
|
0.75
|
0.51–1.11
|
0.714
|
0.483–1.057
|
0.093
|
0.80
|
0.42–1.54
| | | |
|
Histologic type
|
|
Non-HGSC vs. HGSC
|
1.01
|
0.54–1.91
| | | |
0.75
|
0.23–2.45
| | | |
|
FIGO stage
|
|
IV vs. I-III
|
1.14
|
0.74–1.73
| | | |
0.94
|
0.44–2.00
|
0.74
|
0.33–1.64
|
0.461
|
|
Primary treatment strategy
|
|
NAC vs. PDS
|
1.13
|
0.74–1.74
| | | |
2.48
|
1.28–4.79
| | | |
|
Results of initial debulking surgery
|
|
Residual tumor vs. CGR
|
1.15
|
0.79–1.68
| | | |
1.22
|
0.63–2.34
| | | |
|
Platinum-free interval, months
|
|
≥12 vs. 6–12
|
0.44
|
0.29–0.65
|
0.40
|
0.27–0.61
|
<0.001
|
0.37
|
0.19–0.71
|
0.37
|
0.19–0.72
|
0.004
|
|
CA-125 at 1st recurrence, IU/mL
|
|
≥90 vs. <90
|
1.60
|
1.09–2.35
|
1.88
|
1.26–2.82
|
0.002
|
1.77
|
0.92–3.42
|
1.78
|
0.91–3.47
|
0.090
|
|
Residual tumor on CT after #6
|
|
≥1 cm vs. <1cm
|
1.12
|
0.76–1.63
|
1.23
|
0.84–1.81
|
0.294
|
1.79
|
0.91–3.52
|
2.10
|
1.05–4.22
|
0.036
|
|
CA-125 after #6, IU/mL
|
|
≥12.5 vs. <12.5
|
1.58
|
1.08–2.32
|
1.18
|
0.79–1.76
|
0.412
|
1.36
|
0.72–2.58
| | | |
|
Maintenance therapy
|
|
Yes vs. No
|
0.48
|
0.30–0.77
|
0.44
|
0.26–0.72
|
0.001
|
0.69
|
0.29–1.66
|
0.71
|
0.29–1.76
|
0.456
|
|
Extended chemotherapy
|
|
Yes vs. No
|
1.51
|
1.02–2.24
|
1.18
|
0.78–1.78
|
0.428
|
1.32
|
0.70–2.51
|
1.42
|
0.74–2.73
|
0.297
|
